<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158417</url>
  </required_header>
  <id_info>
    <org_study_id>1935</org_study_id>
    <nct_id>NCT01158417</nct_id>
  </id_info>
  <brief_title>Resveratrol in Type2 Diabetes and Obesity</brief_title>
  <official_title>Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleida Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to investigate the effect of resveratrol on inflammatory
      mediators and insulin resistance at the cellular and molecular level in obese non diabetic
      and type 2 diabetic subjects in vivo. This research will investigate the hypothesis that
      resveratrol, when given orally to obese and type 2 diabetic subjects induces a decrease in
      reactive oxygen species (ROS) generation and the pro-inflammatory transcription factor
      nuclear factor-kB (NF-kB) and the inflammatory mediators regulated by it. The hypothesis that
      resveratrol suppresses the high fat, high carbohydrate (HFHC) meal induced inflammatory and
      oxidative response, will also be investigated. This research will also investigate the
      hypothesis that resveratrol intake for 12 weeks improves insulin sensitivity by lowering the
      Homeostasis model assessment of insulin resistance (HOMA-IR), an index of insulin resistance
      and, that resveratrol intake will cause an increase in incretins.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NF-Kb</measure>
    <time_frame>12 weeks</time_frame>
    <description>To investigate the effect of resveratrol on ROS generation and the pro-inflammatory transcription factor NF-kB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GLP-1</measure>
    <time_frame>12 weeks</time_frame>
    <description>To see whether Resveratrol leads to a greater stimulation of the incretin system and secretion/release of GIP and GLP-1 when compared to that following placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol 40 mg oral three times a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>resveratrol 500 mg oral once daily.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol 40 mg oral three times a day</intervention_name>
    <description>Drug</description>
    <arm_group_label>Resveratrol 40 mg oral three times a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol 500 mg oral once daily.</intervention_name>
    <description>Resveratrol 500 mg oral once daily.</description>
    <arm_group_label>resveratrol 500 mg oral once daily.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20 years of age and older

          2. Healthy Obese subjects with BMI &gt; 30

          3. Type 2 Diabetics with BMI &gt; 30

          4. Subjects with good peripheral vein.

          5. Subjects on statins, ACE inhibitors and thiazolidenediones will be allowed as long as
             they are on stable doses of these compounds and the dosage is not changed during the
             course of study.

        Exclusion Criteria:

          1. Subjects on any antioxidant medication

          2. Patient on non-steroidal anti-inflammatory drug

          3. On any agent with significant antioxidant properties.

          4. History of drug or alcohol abuse

          5. Any life threatening disease

          6. Allergy to peanuts, grapes, wine, mulberries.

          7. Pregnant women.

          8. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
             bypass surgery or coronary angioplasty) in the previous four weeks.

          9. Subjects on anticoagulants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaleida Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>115 Flint Road</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaleida Health</investigator_affiliation>
    <investigator_full_name>Paresh Dandona, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

